Design, synthesis and biological evaluation of some novel isoniazid cyclocondensed azetidinones

Karthikeyan Elumalai , Mohammed Ashraf Ali , Manogaran Elumalai , Kalpana Eluri , Sivaneswari Srinivasan , Sujit Kumar Mohanti , Anil Thota
{"title":"Design, synthesis and biological evaluation of some novel isoniazid cyclocondensed azetidinones","authors":"Karthikeyan Elumalai ,&nbsp;Mohammed Ashraf Ali ,&nbsp;Manogaran Elumalai ,&nbsp;Kalpana Eluri ,&nbsp;Sivaneswari Srinivasan ,&nbsp;Sujit Kumar Mohanti ,&nbsp;Anil Thota","doi":"10.1016/j.dit.2013.05.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In the present study, a series of novel azetidinone derivatives synthesized because of its potent antimicrobial and antimycobacterial activity.</p></div><div><h3>Method</h3><p>Compounds (10a–10j) were synthesized by reacting Schiff's base of isoniazid reacted with, chloro acetyl chloride in presence of triethyl amine and 1, 4-dioxane as an efficient catalyst, analyzed for their structures. <em>in vitro</em> antimicrobial and antimycobacterial activity were carried out.</p></div><div><h3>Results</h3><p>Among the synthesized compounds, compound 10b and 10i was found to be the most potent against gram-positive bacteria <em>Bacillus subtilis,</em> gram-negative bacteria <em>Escherichia coli, Mycobacterium tuberculosis</em> CIP <em>and M. tuberculosis</em> H37Rv.</p></div><div><h3>Conclusion</h3><p>A series of novel azetidinone derivatives of biological interest were synthesized and analyzed, suggests that it an interesting compound compared to the current therapeutic agents and are considered to investigate further for the same.</p></div>","PeriodicalId":11284,"journal":{"name":"Drug Invention Today","volume":"5 2","pages":"Pages 100-104"},"PeriodicalIF":0.0000,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dit.2013.05.007","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Invention Today","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0975761913000331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Background

In the present study, a series of novel azetidinone derivatives synthesized because of its potent antimicrobial and antimycobacterial activity.

Method

Compounds (10a–10j) were synthesized by reacting Schiff's base of isoniazid reacted with, chloro acetyl chloride in presence of triethyl amine and 1, 4-dioxane as an efficient catalyst, analyzed for their structures. in vitro antimicrobial and antimycobacterial activity were carried out.

Results

Among the synthesized compounds, compound 10b and 10i was found to be the most potent against gram-positive bacteria Bacillus subtilis, gram-negative bacteria Escherichia coli, Mycobacterium tuberculosis CIP and M. tuberculosis H37Rv.

Conclusion

A series of novel azetidinone derivatives of biological interest were synthesized and analyzed, suggests that it an interesting compound compared to the current therapeutic agents and are considered to investigate further for the same.

几种新型异烟肼环缩合氮杂二酮的设计、合成及生物学评价
本研究合成了一系列新的氮杂啶酮衍生物,因为其具有很强的抗菌和抑菌活性。方法以异烟肼希夫碱与氯乙酰氯在三乙胺和1,4 -二恶烷的催化下反应合成化合物(10a-10j),并对其结构进行分析。体外抗菌和抑菌活性测定。结果化合物10b和10i对革兰氏阳性菌枯草芽孢杆菌、革兰氏阴性菌大肠杆菌、结核分枝杆菌CIP和结核分枝杆菌H37Rv的抑制作用最强。结论合成并分析了一系列具有生物学意义的新型氮杂啶酮衍生物,与现有的治疗药物相比,它是一种令人感兴趣的化合物,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信